Rational design of novel procaspase-3 activators for the targeted therapy of triple-negative breast cancer

Key Points

• Targeted therapy using novel procaspase-3 activators effectively engages caspase pathways.
• In vitro studies demonstrate a 40% increase in procaspase-3 activation in treated cancer cells.
• Analysis of molecular interactions underscores the novel design of procaspase-3 activators.
• Highlighting the need for further clinical validation in triple-negative breast cancer treatments.